Probi
350
SEK
0 %
PROB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
0%
+0.29%
+0.86%
+37.25%
+20.69%
+74.13%
-12.5%
+61.29%
+3,162.69%
Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.
Read moreMarket cap
3.99B SEK
Turnover
4.33M SEK
Revenue
627.69M
EBIT %
1.8 %
P/E
236.49
Dividend yield-%
0.37 %
Financial calendar
28.1
2025
Annual report '24
23.4
2025
Interim report Q1'25
6.5
2025
General meeting '25
ShowingAll content types
Statement from the independent bid committee of Probi in relation to the public takeover offer by Symrise
Probi's Board comments on Symrise's public takeover offer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools